Thelansis

 Lyme disease is a bacterial infection caused by spirochetes of the Borrelia species, specifically the Borrelia burgdorferi (Bb) strain (sensu lato), which can affect multiple organs. It can be categorized into early localized, early disseminated, or late stages, with the body's innate and adaptive immune systems playing a role in generating an inflammatory response that leads to clinical symptoms. Regardless of the stage, most patients treated with appropriate antibiotics significantly improve. Clinical manifestations differ according to the stage of the disease and can include symptoms such as erythema migrans, carditis, central nervous system involvement, and arthritis. However, most patients experience relief from their clinical symptoms when treated with the right antimicrobials. ·        In the United States, the incidence of Lyme disease varies between 8 and 11.5 cases per 100,000 people.   Thelansis’s “Lyme Disease Market Outlook, Ep...

 Lyme disease is a multi-organ animal-borne disease caused by bacteria – spirochetes of the Borrelia species classified as Borrelia burgdorferi (Bb) strain (sensu lato). It can manifest as early localized, early disseminated disease, or late disease. The innate and adaptive immune systems contribute to the inflammatory response resulting in clinical symptoms. Regardless of the clinical presentation, the vast majority of patients who are treated for Lyme disease with short courses of appropriate antibiotics do extremely well. The clinical presentation varies depending on the stage of the illness and includes erythema migrans, carditis, central nervous system disease, and arthritis. Regardless of the clinical presentation, most patients with Lyme disease have a resolution of their clinical symptoms when treated with appropriate antimicrobials. ·        The incidence of Lyme disease in the United States ranges between 8 to 11.5 cases per 100,000 people ...